Sphere Medical has 141,757,872 Ordinary Shares of nominal value £0.01 each in issue.


The Wales Life Sciences Investment Fund 25,000,000 17.64%

Woodford Patient Capital Trust Plc 23,125,000 16.31%

LSP Life Sciences Fund 10,904,000 7.69%

Ortho-Clinical Diagnostics 8,141,250 5.74%

Fidelity Worldwide Investments 6,264,649 4.42%

Octopus Investments 6,250,000 4.41%

Ruffer LLP 5,653,895 3.99%

Royal London Asset Management 5,624,185 3.97%

Herald Investment Management 4,711,965 3.32%





Should be an exciting year ahead with developments.
Anybody had a look at this company?

Interim results due this Thursday 20th September.
Keep an eye out for update on the Proxima 3 device.
This could be a very big money spinner with CE approval..

Sphere Medical CEO Stuart Hendry

Sphere Medical, the Cambridge UK diagnostic device business, saw its first half losses double to £4.2 million after generating zero revenues in the six months to June 30.
But CEO Stuart Hendry and the team insist they have the technology armoury and the strategy to ensure the company doesn’t find itself in a commercial cul-de-sac.

Sphere has a strong pipeline of innovative monitoring and diagnostic devices for the critical care industry.

Dr Hendry said the priority was to secure a commercial partnering deal for its Proxima system – a patient-dedicated arterial blood analyser for use in the intensive care unit and operating room.

He said the partnering proposal had attracted strong interest from a number of leading medical device companies with global distribution capabilities. “Discussions are ongoing and securing a commercial partner remains a core objective for 2012,” he said.

Sphere’s Proxima development programme is progressing across a number of projects – disposable, monitor, software and calibration solutions. Dialogue is underway with the FDA on Proxima including a recent meeting to formulate the regulatory route for full market release of the system.

Despite a revenue-barren six months, the company retains cash and equivalents and money on treasury deposit of £8.3 million (2011: £0.7 million). Operating expenses more than doubled to £4.4m.

Dr Hendry said: “The company’s focus over the first six months of 2012 has been on the continued advancement of the development and commercialisation of our products.

“The process of identifying and concluding a deal for Proxima has been intensive and we are confident of delivering a long term partnership that maximises the potential of this product. We are focused on executing our key deliverables for the second half of 2012.”

Investor presentation this Thursday evening....

**SPHERE MEDICAL INVESTOR FORUM - LONDON - 27TH SEPTEMBER **

The directors of Sphere (AIM:SPHR) will be presenting in London on Thursday 27th September 2012

Venue: Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, W1J 5EB

The presentations will start at 6:00pm and finish at approx 8:00pm. After the presentations are complete the directors will also be available to take questions during a free canapé and wine reception.

Free to attend.

REGISTER HERE: http://www.proactiveinvestors.co.uk/register/event_details/160

SP has fallen since flotation last November '11.
But some very big medical backers involved here...

Anybody going on Thursday??

Hope some good news reported tonight!!!

http://www.shareprice.co.uk/SPHR/SPHERE-MEDICAL-ORD-1P
Good progress...

Cambridge boost for bypass surgery patients

Technology from medical device business Sphere Medical Holding has achieved positive results in trials with anaesthetists involved in bypass surgery at Papworth Hospital in Cambridge UK.
The results will be presented at the Society for Intravenous Anaesthesia Annual Scientific Meeting in Edinburgh on November 29 and 30 and Sphere hopes it will soon be able to drive the product to market in the UK and Japan.

The Cambridge company reports that Pelorus 1500, the world’s first in-vitro diagnostic medical device for the rapid measurement of the intravenous anaesthetic propofol at the point of care, has met its primary end point in the clinical study. It has demonstrated equivalent performance to a gold standard method of analysis, Sphere says.

A total of 111 whole blood samples from 32 patients undergoing cardiopulmonary bypass surgery at Papworth Hospital were analysed. Each sample was tested using both Sphere Medical’s Pelorus 1500 and the current gold standard High Performance Liquid Chromatography (HPLC) reference test. The results from the Pelorus 1500 were said “to show excellent agreement with the reference method.”

Sphere Medical is working with a number of the UK’s leading anaesthetists to investigate novel approaches to take propofol measurements during infusion with the aim of allowing anaesthetists to know the actual – rather than predicted – concentration of propofol thereby creating the personalisation of dosing to the patient.

Have purchased another 400,000 shares to add to their holding..
Holding was 1,331,081 shares......
Now 1,799,363 shares......

Looks a good tie up...

Starting to create some attention and buying..at last......

There is an awful lot of buying in those trades..even my trades are marked as sells?????

Some blue coming through now...seller seems to have cleared....

Shareprophet has tipped this stock recently....large seller has now cleared.......

Got ce approval for Proxima device....Launching device tomorrow.....
Looks interesting now for a punt...imho....:-)

Woodford's first fund investment.....

Proposed Placing and Open Offer



Cambridge, UK, 13 April 2015: Sphere Medical Holding plc (AIM: SPHR.L), a leading provider of innovative monitoring and diagnostic devices for the critical care setting, today announces that it is planning to raise, subject to certain conditions, approximately £12 million (before expenses), by way a Placing pursuant to which 75,000,000 New Ordinary Shares will be issued at 16 pence each to new and existing investors.

Woodford Investment Management, on behalf of its clients, has given a non-binding intent to invest up to £4 million in the Placing and the Wales Fund (being a fund raising up to £100 million focused on life sciences and managed by Arthurian), has given a conditional commitment to invest £4 million in the Placing. The Placing Shares have been conditionally placed by the Joint Brokers with new and existing institutional investors other than those which may be subscribed for by Woodford Investment Management, on behalf of its clients.

Could be finally turning a corner...

You haven't added a EPIC to your thread

Where do I do that or is it to late?

It's not something that we mere mortals can do, but it may be worth asking Ian to do it on this thread.

Thank you guys!!